Comparative Pharmacology
Head-to-head clinical analysis: KLONOPIN versus OXAZEPAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KLONOPIN versus OXAZEPAM.
KLONOPIN vs OXAZEPAM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Benzodiazepine that binds to GABA-A receptors at the benzodiazepine binding site, enhancing the effect of GABA and increasing chloride ion influx, leading to neuronal hyperpolarization and decreased neuronal excitability.
Binds to GABA-A receptor at benzodiazepine binding site, enhancing Cl- ion conductance and increasing inhibitory neurotransmission. Anxiolytic, sedative, hypnotic, anticonvulsant, and muscle relaxant effects.
0.5 mg orally three times daily; maximum 20 mg/day
10-30 mg orally 3-4 times daily; maximum 120 mg/day.
None Documented
None Documented
30-40 hours in adults; prolonged in elderly (up to 50-80 hours) and hepatic impairment; clinical context: steady-state achieved in 5-10 days
Clinical Note
moderateOxazepam + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Oxazepam is combined with Fluticasone propionate."
Clinical Note
moderateOxazepam + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Oxazepam."
Clinical Note
moderateOxazepam + Erythromycin
"The metabolism of Erythromycin can be decreased when combined with Oxazepam."
Clinical Note
moderateOxazepam + Cyclosporine
Terminal elimination half-life is 5-15 hours (mean 8 hours); no active metabolites, thus accumulation is minimal even with repeated dosing.
Renal excretion: ~50-70% as glucuronide metabolites, ~30% as unchanged drug (with enterohepatic recirculation); fecal: <2%
Renal (primarily as glucuronide conjugates, with less than 1% unchanged); biliary/fecal excretion is minimal.
Category C
Category D/X
Benzodiazepine
Benzodiazepine
"The metabolism of Cyclosporine can be decreased when combined with Oxazepam."